Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Inks Non-RNAi Tech-Evaluation Deal with Merck Subsidiary

Premium

Arrowhead Research said this week that it has signed a deal under which an undisclosed Merck subsidiary will evaluate a novel therapeutic monoclonal antibody candidate developed through its human-derived peptide targeting and discovery program.

Merck will be responsible for the costs associated with the arrangement. Additional terms were not disclosed.

Arrowhead picked up the peptide technology through its April acquisition of Alvos Therapeutics (GSN 4/12/2012).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more